Developer docs
API playgroundTry for free, no card

Search company profiles

Osmotica Pharmaceutical

Full company profile

uuid0005eue

Namestring
Osmotica Pharmaceutical
Legal namestring
Osmotica Pharmaceuticals plc
Websiteurl
osmotica.com
Company typeenum
Public
Founded yearint
1980
Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersMarietta, United States
HQ citystring
Marietta
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty pharmaceuticals, drug delivery systems, extended release formulations, contract manufacturing services, neurology therapeutics
Industry4 codes
1Drug Substance–Drug Product Integrated CDMO
CodeHLAGABAGPrimaryYes
2Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
CodeHLAGABABPrimaryNo
3Sterile Fill-Finish & Aseptic Manufacturing CDMO
CodeHLAGABAHPrimaryNo
4Contract Development & Manufacturing for Generics (CDMO/CMO)
CodeHLAIABAIPrimaryNo
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
  • Medical Equipment and Supplies Manufacturing3391
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

The company generates revenue through the sale of pharmaceutical products including five promoted products and approximately 35 non-promoted products. Promoted products include methylphenidate HCl ER tablets, Lorzone, ConZip, Divigel, and OB Complete. Non-promoted products include methylphenidate HCl ER tablets, venlafaxine HCl ER tablets, and prescription and non-prescription dietary supplements.

osmotica.com
2CDMO Services
TypeProfessional Services
Description

Contract Development and Manufacturing Organization (CDMO) providing full service from development through commercial manufacturing with full analytical support. Services include FDA inspected facility with technical expertise in extended and modified release technologies.

osmotica.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Prescription pharmaceutical products sold through healthcare providers and pharmacies
ModelOtherBilling cadenceOther
Notes

Products available only by prescription through healthcare professionals. Pricing determined by insurance coverage, pharmacy pricing, and healthcare provider decisions.

osmotica.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Osmotica Pharmaceutical is a fully-integrated specialty pharmaceutical company that develops, manufactures, and commercializes prescription pharmaceutical products—primarily in specialty neurology and women's health—using its proprietary Osmodex® osmotic drug delivery system. The company also operates a CDMO (Contract Development and Manufacturing Organization) business providing full-service development through commercial manufacturing for complex controlled and modified release formulations.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Osmotica Pharmaceuticals is a fully-integrated biopharmaceutical company and CDMO (Contract Development and Manufacturing Organization) offering a diversified portfolio of five promoted products and approximately 35 non-promoted products. The company's core proprietary technology is the Osmodex® drug delivery system, which enables controlled and modified drug release formulations. Promoted products include Upneeq® for acquired ptosis, OSMOLEX ER™ for Parkinson's disease, Methylphenidate HCl ER 72 mg, Lorzone®, ConZip®, Divigel®, and OB Complete®. The pipeline includes Arbaclofen ER and RVL-1201 in Phase III clinical trials. Products are developed using Osmodex® technology which supports immediate release, controlled release, delayed release, and extended release formulations.

Product and service8 records
1Upneeq®
CategoryPromoted Product
Description

Prescription treatment for acquired ptosis (drooping eyelid); the first and only FDA-approved prescription eyedrop for this condition.

2OSMOLEX ER™ (amantadine)
CategoryPromoted Product
Description

Extended-release tablets for the treatment of Parkinson's Disease and Drug-Induced Extrapyramidal Reactions in adults.

3Methylphenidate HCl ER 72 mg Tablets (M-72)
CategoryPromoted Product
Description

Extended-release methylphenidate tablets for ADHD treatment, incorporating the proprietary Osmodex® drug delivery system.

4Lorzone® (chlorzoxazone USP)
5ConZip® (tramadol hydrochloride)
6Divigel® (estradiol gel) 0.1%
7OB Complete®
8CDMO Services
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Osmotica Pharmaceutical

Specialty Pharmaceuticalsosmotica.com

Osmotica Pharmaceutical firmographics

Firmographics
Name
Osmotica Pharmaceutical
Legal name
Osmotica Pharmaceuticals plc
Website
https://osmotica.com
Company type
Public
Founded year
1980
Operating status
Acquired
Headcount range
251–500 employees
Ownership category
akta.pro rank

Osmotica Pharmaceutical industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Medical Equipment and Supplies Manufacturing (3391)
SIC
Pharmaceutical Preparations (2834)
akta.pro primary industry
Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
akta.pro secondary industries
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

Keywords

  • Specialty pharmaceuticals
  • Drug delivery systems
  • Extended release formulations
  • Contract manufacturing services
  • Neurology therapeutics

Where Osmotica Pharmaceutical is headquartered

Location

Headquarters

HQ city
Marietta
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Osmotica Pharmaceutical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Product Sales: The company generates revenue through the sale of pharmaceutical products including five promoted products and approximately 35 non-promoted products. Promoted products include methylphenidate HCl ER tablets, Lorzone, ConZip, Divigel, and OB Complete. Non-promoted products include methylphenidate HCl ER tablets, venlafaxine HCl ER tablets, and prescription and non-prescription dietary supplements.
  2. CDMO Services: Contract Development and Manufacturing Organization (CDMO) providing full service from development through commercial manufacturing with full analytical support. Services include FDA inspected facility with technical expertise in extended and modified release technologies.

Pricing tiers

ModelBillingPrice
OtherOtherPrescription pharmaceutical products sold through healthcare providers and pharmacies

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Osmotica Pharmaceutical product offering

Product offering

Core offering

Osmotica Pharmaceutical is a fully-integrated specialty pharmaceutical company that develops, manufactures, and commercializes prescription pharmaceutical products—primarily in specialty neurology and women's health—using its proprietary Osmodex® osmotic drug delivery system. The company also operates a CDMO (Contract Development and Manufacturing Organization) business providing full-service development through commercial manufacturing for complex controlled and modified release formulations.

Product overview

Osmotica Pharmaceuticals is a fully-integrated biopharmaceutical company and CDMO (Contract Development and Manufacturing Organization) offering a diversified portfolio of five promoted products and approximately 35 non-promoted products. The company's core proprietary technology is the Osmodex® drug delivery system, which enables controlled and modified drug release formulations. Promoted products include Upneeq® for acquired ptosis, OSMOLEX ER™ for Parkinson's disease, Methylphenidate HCl ER 72 mg, Lorzone®, ConZip®, Divigel®, and OB Complete®. The pipeline includes Arbaclofen ER and RVL-1201 in Phase III clinical trials. Products are developed using Osmodex® technology which supports immediate release, controlled release, delayed release, and extended release formulations.

Differentiator

Problem solved

Functional benefit

Products and services

  • Upneeq® Prescription treatment for acquired ptosis (drooping eyelid); the first and only FDA-approved prescription eyedrop for this condition.
  • OSMOLEX ER™ (amantadine) Extended-release tablets for the treatment of Parkinson's Disease and Drug-Induced Extrapyramidal Reactions in adults.
  • Methylphenidate HCl ER 72 mg Tablets (M-72) Extended-release methylphenidate tablets for ADHD treatment, incorporating the proprietary Osmodex® drug delivery system.
  • Lorzone® (chlorzoxazone USP)
  • ConZip® (tramadol hydrochloride)
  • Divigel® (estradiol gel) 0.1%
  • OB Complete®
  • CDMO Services

Companies that use Osmotica Pharmaceutical

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Osmotica Pharmaceutical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Osmotica Pharmaceutical partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves9 records

Expansion highlights6 records

Osmotica Pharmaceutical competitors and assessment

Company assessment

Market position

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Osmotica Pharmaceutical social profiles

Digital presence

Osmotica Pharmaceutical compliance and trust

Trust signal

Compliance2 records

Osmotica Pharmaceutical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Osmotica Pharmaceutical leadership team

Management profile

Number of profiles

Profiles14 records

Osmotica Pharmaceutical subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Osmotica Pharmaceutical funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Osmotica Pharmaceutical M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Osmotica Pharmaceutical

What does Osmotica Pharmaceutical do?

Osmotica Pharmaceutical is a fully-integrated specialty pharmaceutical company that develops, manufactures, and commercializes prescription pharmaceutical products—primarily in specialty neurology and women's health—using its proprietary Osmodex® osmotic drug delivery system. The company also operates a CDMO (Contract Development and Manufacturing Organization) business providing full-service development through commercial manufacturing for complex controlled and modified release formulations.

Is Osmotica Pharmaceutical a public or private company?

Osmotica Pharmaceutical is a public company. It is classified as corporate owned and is currently acquired.

When was Osmotica Pharmaceutical founded?

Osmotica Pharmaceutical was founded in 1980. It employs 251 to 500 people.

Where is Osmotica Pharmaceutical based?

Osmotica Pharmaceutical is headquartered in Marietta, United States, in the North America region.

How does Osmotica Pharmaceutical make money?

Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are CDMO Services.

Does Osmotica Pharmaceutical have an API?

No public API is recorded for Osmotica Pharmaceutical.

What industry is Osmotica Pharmaceutical in?

Osmotica Pharmaceutical's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American City Business JournalsAlora Pharmaceutical's purchase of Osmotica Pharmaceutical wins Deals of the Year awardAlora Pharmaceuticals' acquisition of Osmotica Pharmaceutical has been recognized as a winner in this year's Deals of the Year Awards. The award honors influential mergers and acquisitions within the Atlanta region, highlighting the strategic transaction between the two pharmaceutical entities.GlobeNewswireUPDATE – Osmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol “RVLP,” Plans to Launch UPNEEQ® into the Medical Aesthetics Market, and Provides FouOsmotica Pharmaceuticals changed its name to RVL Pharmaceuticals and launched a new ticker, RVLP. Q4 2021 UPNEEQ sales grew 41% to $3.1 million, and the company guided Q4 2022 net sales to $20-25 million. A full national launch into medical aesthetics is expected in February 2022.BenzingaOsmotica Pharma Announces Rebranding As RVL Pharma, Issues Q4 Sales OutlookOsmotica Pharmaceuticals plc announced it will rebrand as RVL Pharmaceuticals plc and begin trading under the ticker RVLP on NASDAQ, reflecting a strategic shift to position the company as a growth-focused entity in eye care and medical aesthetics. The company reported strong performance for its FDA-approved product Upneeq, with Q4 FY21 net sales of $3.1 million, representing approximately 41% sequential growth, and cumulative unique pharmacy prescribers reaching 10,500 by year-end 2021. RVL Pharma is targeting Q4 FY22 net sales of $20-25 million combined between eyecare and medical aesthetics.BenzingaOsmotica Pharmaceuticals Says Q4 Net Sales For UNPEEQ Targeted To Range From $20M-$25MOsmotica Pharmaceuticals announced that its targeted net sales range for the fourth quarter for its product UNPEEQ is $20 million to $25 million. The article consists primarily of promotional content and advertisements from Benzinga, with no additional substantive reporting or context provided regarding the company's performance.GlobeNewswireOsmotica Pharmaceuticals plc to Host UPNEEQ® Overview and Business Update Call on January 19, 2022Osmotica Pharmaceuticals will host a call on January 19, 2022, at 8:30 a.m. ET with CEO Brian Markison and COO James Schaub to discuss UPNEEQ trends and pending expansion into medical aesthetics. The webcast will be available via the company's website.PR NewswireThinking about buying stock in Allakos, 22nd Century Group, Osmotica Pharmaceuticals, Banco Santander SA, or Opko Health?InvestorsObserver issued PriceWatch Alerts for stocks including Allakos, 22nd Century Group, Osmotica Pharmaceuticals, Banco Santander SA, and Opko Health. The alerts are based on a proprietary scoring methodology that evaluates short-term technical, long-term technical, and fundamental factors to determine investment suitability. InvestorsObserver provides these tools to help investors make decisions regarding stocks or options.Benzinga18 Stocks Moving in Thursday's Pre-Market SessionThe article lists various stocks moving in pre-market trading, highlighting significant price changes for companies such as Pasithea Therapeutics, Osmotica Pharmaceuticals, and JD.com. Key drivers include new clinic expansions, analyst rating initiations, clinical trial data releases, and strategic corporate actions like Tencent's share distribution affecting JD.com. The report covers both gainers and losers across different sectors without focusing on a single specific event.GlobeNewswireOsmotica Pharmaceuticals plc to Present at H.C. Wainwright Bioconnect ConferenceOsmotica Pharmaceuticals announced that CEO Brian Markison, COO James Schaub, and CFO Andrew Einhorn will present virtually at the H.C. Wainwright Bioconnect Conference on January 10, 2022. The on-demand webcast will be available for 30 days via the company's website.GlobeNewswireOsmotica Pharmaceuticals plc to Provide Third Quarter 2021 Business and Financial Update on November 15, 2021Osmotica Pharmaceuticals will release its third quarter 2021 financial results on November 15, 2021, after U.S. market close. The company will host a conference call with its CEO, COO, and CFO at 4:30 p.m. ET, with a live webcast available on its website.GlobeNewswireOsmotica Pharmaceuticals plc Announces Debt Financing from Athyrium Capital Management of up to $100 MillionOsmotica Pharmaceuticals entered a note purchase agreement for up to $100 million in senior secured notes with Athyrium Capital Management. The deal will issue $55 million at closing, with additional $20 million and $25 million available subject to conditions. The notes mature in October 2026.